by qfrsolutions | Dec 9, 2016 | News
Source: Aclaris Therapeutics’ investigational new drug (IND) application for ATI-50001, an orally administered investigational Janus Kinase (JAK) inhibitor, for the potential treatment of alopecia totalis and alopecia universalis has cleared the 30-day review...
by qfrsolutions | Dec 1, 2016 | News
Source: Globe Newswire Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced top-line results from the Company’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV....
by qfrsolutions | Nov 16, 2016 | News
Source: Novartis’ Cosentyx and Celgene’s Otezla aren’t just battling it out in the psoriasis arena. As of early this year, they’re competing in psoriatic arthritis, too—and each drugmaker made its case this week with new data in that...
by qfrsolutions | Nov 8, 2016 | News
Source: The Wall Street Journal Valeant Pharmaceuticals International Inc. cut its annual outlook again Tuesday as the drug company, struggling to remake its business after a series of missteps, signaled its turnaround may take longer than expected. Shares of the...
by qfrsolutions | Nov 1, 2016 | News
Source: LinkedIn Thank you to our Elite Talent Network!! QFR Solutions has earned the Top spot (#1) in LinkedIn’s Top 25 of LinkedIn’s Most Socially Engaged Staffing Agencies 2016. There were 60,000 staffing firms considered with 57,000 of these being in our category...
by qfrsolutions | Oct 27, 2016 | News
Source: FierceBiotech Biotech IPOs are faring well this fall. That’s despite tough talk from U.S. politicians on biopharma pricing, as the topic has become a focal point in the presidential elections. In a second IPO of the week, Myovant Sciences ($MYOV) raised...
